Obesity, Obesity, Morbid
Conditions
Keywords
Bariatric surgery
Brief summary
Sleeve gastrectomy (SG) has become the most commonly performed weight loss surgery, accounting for 60% of all bariatric operations worldwide. While technically easier with less side-effects and nutritional risks than other operations, SG is also associated with a higher risk of failure (20 to 40%). In such case, the most effective option consists in adding an intestinal bypass called the Biliopancreatic Diversion with Duodenal Switch (BPD-DS). This surgery is, however, technically challenging and yields a significant risk of complications, nutritional deficiencies or gastro-intestinal side-effects. Recently, a simplified version of the Standard DS, called Single-Anastomosis Duodenoileal Switch (SADI-S) was endorsed by surgical societies as one of the approved bariatric procedures. There is currently no prospective or randomized data to support the effectiveness of this new procedure, especially as a revisional approach. The Overall Objective of this randomized controlled trial project is to establish the clinical benefits of the SADI-S as a revisional surgery after SG, while also considering critical issues related to sex and gender. The investigator Overall Hypothesis is that the SADI-S represents a relevant revisional option for weight loss and metabolic recovery in women and men suffering from severe obesity who had a previous SG. The investigator propose to address the following research question. Research Question: What are the clinical effects of SADI-S compared to standard DS when used as a revisional procedure after SG, in patients with obesity? Participants who need revisional surgery after SG will be enrolled in a prospective, randomized, double-blind (patient-evaluator), non-inferiority trial comparing SADI-S vs DS. The primary outcome will be 12-month excess weight loss. Secondary outcomes will be perioperative complications, risk of malnutrition, quality of life and gastrointestinal side effects. The investigator hypothesize that SADI-S offers similar weight loss compared to standard DS, but a lower risk of complications and nutritional deficiencies. With the increase in the number of bariatric operations performed worldwide and the recent endorsement of the SADI-S as a regular procedure, reliable clinical data are urgently needed. The present proposal will directly address this knowledge gap.
Interventions
Standard duodenal switch as second stage surgery after a sleeve gastrectomy (100cm common channel and 150cm alimentary limb)
Single-anastomosis duodeno-ileal anastomosis as second stage surgery after a sleeve gastrectomy (250cm common channel)
Sponsors
Study design
Eligibility
Inclusion criteria
* had sleeve gastrectomy a minimum of 18 months before * still meet the NIH criteria for bariatric surgery (BMI≥35kg/m2 with major comorbidities or BMI≥40kg/m2) or patients with EWL\<50% or significant weight regain (≥20%EWL)
Exclusion criteria
* general contra-indication for bariatric surgery * BMI\<35kg/m2 * pregnancy * cirrhosis * abnormal bowel habits including irritable bowel syndrome and inflammatory bowel disease
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Excess weight loss | 12 month | Percentage of excess weight loss mobilized in response to surgery |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Risk of malnutrition | from baseline to 60 months | Risk of malnutrition assessed through measurement of its risk being mild (albumin\<35g\\L), moderate (albumin\<30g/L) or severe (albumin\<25g/L) |
| Change in quality of life (SF-36) | from baseline to 60 months | 36-item short form survey evaluating quality of life on a scale form 0 to 100 |
| Change in quality of life (BAROS) | from baseline to 60 months | Bariatric Analyses and Reporting Outcomes System score form -7 to 9 |
| Change in quality of life (QLaval) | from baseline to 60 months | Laval questionnaire evaluating quality of life on 6 aspects on a scale from 0 to 7 |
| Gastro-intestinal side effects | from baseline to 60 months | Evaluation of gastro-intestinal side effects with the Gastro-Intestinal Quality of Life Index from 0 to 144 |
| Change in nutritional status (calcium) | from baseline to 60 months | Change in nutritional status based on blood analysis of calcium (mmol/L) |
| Change in nutritional status (ferritin) | from baseline to 60 months | Change in nutritional status based on blood analysis of ferritin (ug/L) |
| Change in nutritional status (TIBC) | from baseline to 60 months | Change in nutritional status based on blood analysis of TIBC (umol/L) |
| Change in nutritional status (iron) | from baseline to 60 months | Change in nutritional status based on blood analysis of iron (umol/L) |
| Peroperative complications | from baseline up to 60 months | Complications graded with Clavien classification |
| Change in nutritional status (transferrin) | from baseline to 60 months | Change in nutritional status based on blood analysis transferrin (g/L) |
| Change in nutritional status (vitamin A) | from baseline to 60 months | Change in nutritional status based on blood analysis of vitamin A (umol/L) |
| Change in nutritional status (vitamin D3) | from baseline to 60 months | Change in nutritional status based on blood analysis of vitamin D3 (nmol/L) |
| Change in nutritional status (parathormone) | from baseline to 60 months | Change in nutritional status based on blood analysis parathormone (ng/L) |
| Change in food intake | from baseline to 60 months | Evaluation of the change in food intake using a web-based food frequency questionnaire (kcal/day) |
| Change in eating behavior | from baseline to 60 months | Change of eating behavior using the Three-Factor Eating Questionnaire evaluating cognitive restraint of eating on a scale from 0 to 20, disinhibition on a scale from 0 to 16 and hunger on a scale from 0 to 15 |
| Change in food addiction | from baseline to 60 months | Change of eating behavior using the Yale Food Addiction Scale that includes a symptom count scale from 0 to 7 reflecting the number of addiction-like criteria endorsed and a dichotomous evaluation that indicates whether a threshold of three or more symptoms plus clinically significant impairment or distress has been met |
| Change in binge eating behavior | from baseline to 60 months | Change of eating behavior using the Binge Eating scale from 0 to 46 |
| Evolution of obesity related diseases | from baseline to 60 months | Remission rate for comorbidities, including T2D, hypertension, dyslipidemia, sleep apnea according to the ASMBS definition of outcomes reporting |
| Change in nutritional status (prealbumin) | from baseline to 60 months | Change in nutritional status based on blood analysis of prealbumin (g/L) |
Countries
Canada